2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patientsTreatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung
Ramalingam S, Dinan M, Crawford J. Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. Clinical Lung Cancer 2021, 22: e646-e653. PMID: 33582071, DOI: 10.1016/j.cllc.2020.12.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMetastatic non-small cell lung cancerCommunity-based centersAcademic centersMetastatic non-small cell carcinomaNon-small cell carcinomaStudy periodPrimary end pointNational Cancer DatabaseCell lung cancerSquamous cell carcinomaCancer-related deathMost cancer-related deathsTreatment-related improvementOverall survivalSurvival gapSurvival disparitiesImproved survivalCell carcinomaLung cancerCancer DatabaseRetrospective analysisNew therapiesPatientsEnd point
2015
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer
Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal Of Clinical Oncology 2015, 33: 2370-2375. PMID: 26077238, DOI: 10.1200/jco.2014.59.8391.Peer-Reviewed Original ResearchConceptsCervical lymph node metastasisAge 45 yearsLymph node metastasisPapillary thyroid cancerMetastatic lymph nodesAmerican Joint CommitteeOverall survivalNode metastasisMetastatic nodesLymph nodesNodal metastasisThyroid cancerJoint CommitteeAssociation of OSPatients age 45 yearsNational Cancer Data BaseCurrent American Joint CommitteeMore positive nodesLow-risk diseasePresence of lymphAdditional mortality riskPositive nodesPreoperative screeningAdult patientsSEER databaseAdjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyPapillary thyroid cancerIntermediate-risk papillary thyroid cancerAdjuvant radioactive iodine therapyIntermediate-risk PTC patientsImproved overall survivalIntermediate-risk patientsOverall survivalRisk of deathRAI therapyIodine therapyPTC patientsThyroid cancerAmerican Thyroid Association riskLong-term prognosisAmerican Joint CommissionCommon endocrine malignancyPaucity of dataTotal thyroidectomyAdult patientsMultivariate adjustmentClinical factorsAggressive variantStage T3Patient groupImpact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years
Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of Extent of Surgery on Survival for Papillary Thyroid Cancer Patients Younger Than 45 Years. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 115-121. PMID: 25337927, PMCID: PMC5399499, DOI: 10.1210/jc.2014-3039.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer patientsTotal thyroidectomyOverall survivalThyroid cancer patientsImpact of extentYears of ageCancer patientsNational Cancer Data BaseUnadjusted overall survivalLymph node diseaseExtent of resectionEnd Results (SEER) datasetAdult patientsClinical characteristicsExcellent prognosisNode diseasePathologic factorsImproved survivalThyroid lobectomyTumor sizeCurrent guidelinesMultivariable modelingLobectomyMAIN OUTCOMEThyroidectomy
2014
Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerExtent of surgeryTotal thyroidectomyOverall survivalTumor sizeDistant metastasisThyroid cancerSurvival advantagePTC tumorsRadioactive iodine treatmentLarge contemporary cohortOverall survival advantageUnderwent total thyroidectomyProportional hazards modelPresence of nodalMultivariable adjustmentAdult patientsClinical factorsContemporary cohortMultifocal diseaseAbsolute indicationMale sexTumors 1.0Black racePTC patientsTreatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States
Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, Sosa JA. Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States. Annals Of Surgical Oncology 2014, 21: 3509-3514. PMID: 25069860, PMCID: PMC4515350, DOI: 10.1245/s10434-014-3931-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultAgedDatabases, FactualElective Surgical ProceduresFemaleFollow-Up StudiesHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayMaleMiddle AgedNeoplasm StagingOutcome and Process Assessment, Health CarePractice Patterns, Physicians'RegistriesReoperationSurvival RateWorkloadConceptsHigh-volume centersLow-volume centersHospital case volumeOverall survivalTreatment patternsCase volumeRegional lymph node evaluationAggressive surgical resectionLymph node evaluationPrimary adrenal malignancyMedian overall survivalNational Cancer DatabasePostoperative mortality rateBackgroundAdrenocortical carcinomaChemotherapy useAggressive treatmentRadical resectionReadmission ratesSurgical resectionAdrenal malignancyCarcinoma AssociatedClinical outcomesTumor characteristicsACC patientsAggressive diseaseImpact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States
Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States. Annals Of Surgical Oncology 2014, 21: 3515-3521. PMID: 24841347, PMCID: PMC4510956, DOI: 10.1245/s10434-014-3769-4.Peer-Reviewed Original ResearchConceptsNonfunctional pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsExtent of surgerySmall Nonfunctional Pancreatic Neuroendocrine TumorsFive-year OSOverall survivalMalignant potentialNeuroendocrine tumorsNational Cancer Data BaseLymph node dissectionLymph node resectionKaplan-Meier analysisType of surgeryLog-rank testUncertain malignant potentialImpact of extentNode dissectionNode resectionTotal pancreatectomyPatient characteristicsRegional lymphRegional lymphadenectomySurgical resectionImproved survivalDistant metastasis
2012
Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003. Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.Peer-Reviewed Original ResearchConceptsPositron emission tomographyOverall survivalStage migrationMedicare beneficiariesAdvanced diseasePET useEnd Results-Medicare dataEmission tomographyProportion of patientsStage IV diseaseCell lung cancerSelection biasUpstaging of diseaseGreater overall survivalStage-specific survivalStudy criteriaLung cancerSurvival AssociatedImproved outcomesRetrospective analysisStage distributionNSCLCPatientsDiseaseSurvival